Oasmia to move all of its veterinary assets to U.S. to catch $16bn market
Staff Writer |
Oasmia Pharmaceutical of Sweden, a developer of drugs within human and veterinary oncology, plans to move all of the company’s veterinary assets including Paccal Vet and Doxophos Vet, to the United States.
Article continues below
]
The company’s key objective within veterinary medicine is to successfully transition the products on a broader scale to a larger number of veterinary clinics.
Prior to this announcement, Paccal Vet-CA1 has been available to a limited number of oncology specialists.
Oasmia anticipates that changing the treatment regime by lowering the dose to reduce side effects and improve comfort for companion animals, the product will become far more attractive to veterinarians and pet owners.
In order to achieve this goal, the company has withdrawn its current label which is conditionally approved and plan to initiate a new study confirming the changed dosing regimen.
The company plans a a proof of concept/dose intensity study. The clinical program with Doxophos Vet is ongoing, with the expectation to communicate the results from a proof of concept study during the spring of 2017.
In order to provide an ideal environment for Oasmia’s veterinary division to successfully achieve strategic development and collaborations, all rights for Paccal Vet and Doxophos Vet intents to be transferred to the fully owned subsidiary in the United States.
With approximately 42,000 general veterinary practitioners in the United States and 2,500 entering the job force each year, Oasmia has identified tremendous market opportunity for Paccal Vet and Doxophos Vet.
Small animal (dog and cat) medicine(s) represent the bulk of the approximately $16 billion market for pet treatment products, a number that has nearly doubled since 2001.
By reducing side effects and making the treatment more appealing to general practitioners, Oasmia believes it can garner significant market share as the industry continues to expand. ■